Dr. Evandro D. Bezerra, M.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 77
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
OH license 35.145285 -
Hematology & Oncology Physician
MN license 65153 · WA license FE60449483 -
Internal Medicine Physician
WA license ML60654966
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cleveland Clinic Cleveland, OH
- Hillcrest Hospital Mayfield Heights, OH
- Akron General Medical Center Akron, OH
- Fairview Hospital Cleveland, OH
- Cleveland Clinic Avon Hospital Avon, OH
Medical groups
- Cleveland Clinic (7,090 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 77
- Services billed
- 275
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 129 | 33 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 56 | 18 |
| Established patient office or other outpatient visit, 40-54 minutes | 54 | 26 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 17 | 17 |
| Hospital discharge day management, more than 30 minutes | 15 | 15 |
| Established patient office or other outpatient visit, 30-39 minutes | 13 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Columbus, OH | 16 |
| Magnesium Sulfate | 12 |
| Jakafi (ruxolitinib phosphate) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 5 payments worth $7,954 in total to this clinician.
| Alexion Pharmaceuticals, Inc. | $7,954 |
|---|
| Consulting Fee | $7,800 |
|---|---|
| Travel and Lodging | $77.76 |
| Food and Beverage | $76.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. Jan 9, 2025 | Consulting Fee | $7,800 |
| Alexion Pharmaceuticals, Inc. Jan 9, 2025 | Travel and Lodging travel to Boston, MA Company’s descriptionConsulting Expenses | $50.00 |
| Alexion Pharmaceuticals, Inc. Jan 9, 2025 | Travel and Lodging travel to Boston, MA Company’s descriptionConsulting Expenses | $27.76 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $119,982 in research payments for these studies, mostly to the institutions running them.
- A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5)
Kite Pharma, Inc. - A Phase 3, Randomized, Double Blind, Placebo Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)
Alexion Pharmaceuticals, Inc. - A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA 7)
Kite Pharma, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.